Avita (RCEL) Q1 2026 Earnings Call Transcript

Avita Medical reported Q1 revenue of $19.3 million, up 4% year over year and 10% sequentially, with management reaffirming full-year 2026 guidance of $80 million to $85 million. RECELL reimbursement is now fully clarified across all seven MACs, and the company signed a new BARDA agreement with a $25.5 million ceiling, including $3.9 million of guaranteed revenue amortized over 10 years. Gross margin fell to 81.7% from 84.7% due to inventory reserves and product mix, but operating expenses declined 11% and management signaled lower cash use in Q2.

Analysis

RCEL’s setup is less about a one-quarter revenue beat and more about a regime change in order quality. The market has been treating the name like a reimbursement beta trade, but once payment uncertainty is largely removed, the earnings power should start to reflect procedure volume, account penetration, and mix rather than episodic buying behavior. That usually compresses the gap between sell-side revenue estimates and actuals over 2-3 quarters because forecasting error falls faster than the top line rises.

The more interesting second-order effect is margin durability versus mix dilution. Cohealyx and PermeaDerm may lower reported gross margin percentages, but they can improve gross profit dollars while adding relatively little opex, which creates a hidden operating leverage path if management keeps the cost base flat. In other words, the company can look “worse” on margin optics while still improving unit economics; that tends to be misread by momentum screens and can keep valuation anchored until several quarters of consistent execution force a rerating.

The largest near-term risk is not demand rollback, but the company overearning credibility too early. If second-quarter cash burn does not fall materially as promised, the stock will likely trade back to liquidity stress rather than growth optionality. A second risk is that Cohealyx adoption remains committee-led and therefore slow-moving; if VAC throughput stalls, investors may have to wait until late 2026 for the portfolio story to become self-evident. The contrarian angle is that this may be a better Q2/Q3 operating momentum trade than a “story stock” winner—guidance may stay conservative precisely because management wants proof before monetizing the reset.

Key Decisions for Investors

• Long RCEL into the next 1-2 quarterly print window; best risk/reward is on a pullback after initial post-earnings enthusiasm fades, with upside if Q2 cash burn visibly resets lower and sequential growth persists.
• Buy RCEL common and finance with out-of-the-money puts 3-6 months out; this captures a rerating if reimbursement normalization translates into cleaner cash conversion while limiting downside if adoption slows or dilution risk returns.
• Pair trade: long RCEL / short a lower-quality wound-care or small-cap medtech name with stretched expectations; RCEL’s catalyst path is now operational, while many peers still rely on multiple expansion without reimbursement normalization.
• If options liquidity is sufficient, consider RCEL call spreads for a 2-3 quarter horizon; the key driver is not explosive growth but estimate revisions as revenue cadence becomes more predictable.
• Trim or hedge if management’s second-quarter cash commentary fails to show a sharp inflection; that would re-open financing overhang and likely erase the “stabilization” premium quickly.